EXEGENICS INC

FORM SC 13G/A
(Amended Statement of Ownership)

Filed 4/9/1998

Address	1250 PITTSFORD-VICTOR ROAD BUILDING 200, SUITE 280 PITTSFORD, New York 14534
Telephone	585-218-4368
CIK	0000944809
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

Generated by **EDGAR Online Pro**
http://pro.edgar-online.com

EDGAR Online

Contact **EDGAR Online**
Customer Service: 203-852-5666
Corporate Sales: 212-457-8200

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934
(Amendment No.____1_____)*

Cytoclonal Pharmaceutics Inc.

(Name of Issuer)

Common Stock, $.01 par value

(Title of Class of Securities)

23282G105
(CUSIP Number)

Check the following box if a fee is being paid with this statement [ ].

(A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Kinder Investments, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ]
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION New York

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		
	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 708,000
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 708,000

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 708,000
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.1%
12	TYPE OF REPORTING PERSON* PN

*SEE INSTRUCTIONS BEFORE FILLING OUT

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Peyser Associates, LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

New York

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 708,000
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 708,000

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

708,000

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

8.1%

12 TYPE OF REPORTING PERSON*

CO.

*SEE INSTRUCTIONS BEFORE FILLING OUT

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Brian A. Wasserman

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 708,000
	6	SHARED VOTING POWER 0
	7	SOLE DISPOSITIVE POWER 708,000
	8	SHARED DISPOSITIVE POWER 0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

708,000

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

8.1%

12 TYPE OF REPORTING PERSON*

IN

*SEE INSTRUCTIONS BEFORE FILLING OUT

 Item 1.
(a) Name of Issuer:

Cytoclonal Pharmaceutics Inc.

(b) Address of Issuer's Principal Executive Offices:

9000 Harry Hines Boulevard
Dallas, TX 75232

Item 2.
(a) Name of Person Filing:

Kinder Investments, L.P. ("Kinder Investments"); Peyser Associates, LLC ("Peyser"), the general partner of Kinder Investments; and Brian A. Wasserman ("Wasserman"), the managing member of Peyser (together, the "Reporting Parties"). See attached Exhibit A which is their agreement to file this Schedule on behalf of each of them.

(b) Address of Principal Business Office or, if None, Residence:

The Reporting Parties' business address is 1500 Hempstead Turnpike, East Meadow, New York 11554.

(c) Citizen:

Kinder Investments is a New York partnership, Peyser is a New York corporation, and Wasserman is a citizen of the United States.

(d) Title of Class of Securities:
Common Stock, $.01 par value ("shares").

(e) CUSIP#:
23282G105

Item 4. Ownership:

(a)(b) As of December 31, 1997, the Reporting Parties may be deemed to beneficially own 708,000 shares or 8.1% of the Issuer's shares as follows: (i) 668,000 shares owned directly by Kinder Investments, and (ii) warrants to purchase 40,000 shares at an exercise price of $3.75 per share, expiring November 2, 2000 owned directly by Kinder Investments.

(c) Wasserman, as the managing member of Peyser, has sole voting and dispositive control of shares owned by Kinder Investments.

Item 5. Ownership of Five Percent or Less of a Class:

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding Company:

Not applicable.

Item 8. Identification and Classification of Members of the Group:

Not applicable.

Item 9. Notice of Dissolution of Group:

Not applicable.

Item 10. Certification:
By signing below we certify that to the best of our knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as participant in any transaction having such purpose of effect.

SIGNATURES

After reasonable inquiry and to the best knowledge and belief of the Reporting Persons, each such person or entity certifies that the information set forth in this statement is true, complete and correct.

Kinder Investments, L.P.

Dated: April 8, 1998
New York, New York

By: /s/ Brian A. Wasserman
Brian A. Wasserman
Managing Member
Peyser Associates, LLC

Peyser Associates, LLC

Dated: April 8, 1998
New York, New York

By: /s/ Brian A. Wasserman
Brian A. Wasserman
Managing Member

Dated: April 8, 1998

/s/ Brian A. Wasserman
Brian A. Wasserman

EXHIBIT A

AGREEMENT

JOINT FILING OF SCHEDULE 13G

The Undersigned hereby agree to jointly prepare and file with regulatory authorities a Schedule 13G and any future amendments thereto reporting each of the undersigned's ownership of securities of Cytoclonal Pharmaceutics Inc. and hereby affirm that such Schedule 13G is being filed on behalf of each of the undersigned.

Kinder Investments, L.P.

Dated: April 8, 1998
New York, New York

By: /s/ Brian A. Wasserman
Brian A. Wasserman
Managing Member
Peyser Associates, LLC

Peyser Associates, LLC

Dated: April 8, 1998
New York, New York

By: /s/ Brian A. Wasserman
Brian A. Wasserman
Managing Member

Dated: April 8, 1998

/s/ Brian A. Wasserman
Brian A. Wasserman

End of Filing

Powered By EDGAR Online

© 2005 | EDGAR Online, Inc.